key: cord-0023154-0fu74czw
authors: Ringelstein, Marius; Ayzenberg, Ilya; Lindenblatt, Gero; Fischer, Katinka; Gahlen, Anna; Novi, Giovanni; Hayward-Könnecke, Helen; Schippling, Sven; Rommer, Paulus S.; Kornek, Barbara; Zrzavy, Tobias; Biotti, Damien; Ciron, Jonathan; Audoin, Bertrand; Berthele, Achim; Giglhuber, Katrin; Zephir, Helene; Kümpfel, Tania; Berger, Robert; Röther, Joachim; Häußler, Vivien; Stellmann, Jan-Patrick; Whittam, Daniel; Jacob, Anu; Kraemer, Markus; Gueguen, Antoine; Deschamps, Romain; Bayas, Antonios; Hümmert, Martin W.; Trebst, Corinna; Haarmann, Axel; Jarius, Sven; Wildemann, Brigitte; Grothe, Matthias; Siebert, Nadja; Ruprecht, Klemens; Paul, Friedemann; Collongues, Nicolas; Marignier, Romain; Levy, Michael; Karenfort, Michael; Deppe, Michael; Albrecht, Philipp; Hellwig, Kerstin; Gold, Ralf; Hartung, Hans-Peter; Meuth, Sven G.; Kleiter, Ingo; Aktas, Orhan
title: Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
date: 2021-11-16
journal: Neurol Neuroimmunol Neuroinflamm
DOI: 10.1212/nxi.0000000000001100
sha: 1f4da15cf697e49c2c65a2c4964a3961550ee06a
doc_id: 23154
cord_uid: 0fu74czw

BACKGROUND AND OBJECTIVES: To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–IgG–associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD). METHODS: Annualized relapse rate (ARR), Expanded Disability Status Scale score, MRI, autoantibody titers, pain, and adverse events were retrospectively evaluated in 57 patients with MOGAD (n = 14), aquaporin-4 (AQP4)-IgG seropositive (n = 36), and seronegative NMOSD (n = 7; 12%), switched to TCZ from previous immunotherapies, particularly rituximab. RESULTS: Patients received TCZ for 23.8 months (median; interquartile range 13.0–51.1 months), with an IV dose of 8.0 mg/kg (median; range 6–12 mg/kg) every 31.6 days (mean; range 26–44 days). For MOGAD, the median ARR decreased from 1.75 (range 0.5–5) to 0 (range 0–0.9; p = 0.0011) under TCZ. A similar effect was seen for AQP4-IgG+ (ARR reduction from 1.5 [range 0–5] to 0 [range 0–4.2]; p < 0.001) and for seronegative NMOSD (from 3.0 [range 1.0–3.0] to 0.2 [range 0–2.0]; p = 0.031). During TCZ, 60% of all patients were relapse free (79% for MOGAD, 56% for AQP4-IgG+, and 43% for seronegative NMOSD). Disability follow-up indicated stabilization. MRI inflammatory activity decreased in MOGAD (p = 0.04; for the brain) and in AQP4-IgG+ NMOSD (p < 0.001; for the spinal cord). Chronic pain was unchanged. Regarding only patients treated with TCZ for at least 12 months (n = 44), ARR reductions were confirmed, including the subgroups of MOGAD (n = 11) and AQP4-IgG+ patients (n = 28). Similarly, in the group of patients treated with TCZ for at least 12 months, 59% of them were relapse free, with 73% for MOGAD, 57% for AQP4-IgG+, and 40% for patients with seronegative NMOSD. No severe or unexpected safety signals were observed. Add-on therapy showed no advantage compared with TCZ monotherapy. DISCUSSION: This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and AQP4-IgG+ NMOSD.

days). For MOGAD, the median ARR decreased from 1.75 (range 0. to 0 (range 0-0.9; p = 0.0011) under TCZ. A similar effect was seen for AQP4-IgG+ (ARR reduction from 1.5 [range 0-5] to 0 [range 0-4.2]; p < 0.001) and for seronegative NMOSD (from 3.0 [range 1.0-3.0] to 0.2 [range 0-2.0]; p = 0.031). During TCZ, 60% of all patients were relapse free (79% for MOGAD, 56% for AQP4-IgG+, and 43% for seronegative NMOSD). Disability follow-up indicated stabilization. MRI inflammatory activity decreased in MOGAD (p = 0.04; for the brain) and in AQP4-IgG+ NMOSD (p < 0.001; for the spinal cord). Chronic pain was unchanged. Regarding only patients treated with TCZ for at least 12 months (n = 44), ARR reductions were confirmed, including the subgroups of MOGAD (n = 11) and AQP4-IgG+ patients (n = 28). Similarly, in the group of patients treated with TCZ for at least 12 months, 59% of them were relapse free, with 73% for MOGAD, 57% for AQP4-IgG+, and 40% for patients with seronegative NMOSD. No severe or unexpected safety signals were observed. Add-on therapy showed no advantage compared with TCZ monotherapy.

This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and AQP4-IgG+ NMOSD.

Myelin oligodendrocyte glycoprotein (MOG)-IgG-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD) with or without anti-aquaporin-4 (AQP4)-IgG are antibody-mediated, chronic inflammatory CNS conditions in most cases. [1] [2] [3] [4] Although the clinical presentation with unilateral or bilateral optic neuritis (ON), longitudinally extensive transverse myelitis, or brain stem syndromes may be similar in MOGAD and NMOSD, demographic, clinical, imaging, and pathophysiologic findings strongly suggest the presence of 2 distinct disease entities. [4] [5] [6] [7] [8] As MOGAD, excluding acute disseminated encephalomyelitis (ADEM), and NMOSD typically follow a relapsing course in adults, 3, 9 attack prevention is key to avoid disability accumulation. Recently, a variety of therapeutic strategies such as CD19/20-mediated B-cell depletion, 10, 11 complement inhibition, 12 and interleukin-6 (IL-6) receptor blockade 13, 14 were successfully investigated in pivotal NMOSD trials, particularly in AQP4-IgG+ patients. Yet, insights concerning the effectiveness and safety of such agents in MOGAD are scarce. IL-6 plays an important role in the pathophysiology of NMOSD. 15 Increased levels were detected in the serum and CSF, particularly during attacks. 16 IL-6 promotes the differentiation of inflammatory Th17 cells 17 and the production of AQP4-IgG by B cell-derived plasmablasts in NMOSD 18 and increases the permeability of the blood-brain barrier, 19 facilitating CNS inflammation. The efficacy of IL-6 receptor blockade in AQP4-IgG+ NMOSD was suggested by studies using tocilizumab (TCZ) in adults and children [20] [21] [22] [23] [24] [25] [26] and demonstrated by 2 pivotal trials of satralizumab, whereas the effect in AQP4-IgG-seronegative patients was less evident. 13, 14 As AQP4-IgG+ NMOSD and MOGAD both display antibody-and complement-mediated CNS injury and similar inflammatory CSF profiles (with elevated IL-6), 27, 28 IL6-blockade may also be beneficial in MOGAD, supported by recent case reports. 23, 25, 26, [29] [30] [31] [32] [33] This retrospective multicenter study explored the safety and efficacy of TCZ in patients with MOGAD and is able to connect these findings with the effects of TCZ in classical (i.e., AQP4-IgG+) or double-seronegative NMOSD.

Fifty-seven patients with relapsing MOGAD (n = 14), 34 excluding ADEM, classical AQP4-IgG+ NMOSD (n = 36), or double-seronegative NMOSD (n = 7), mainly of Caucasian descent (n = 50; Table 1 ), from neurologic departments of 23 tertiary referral centers in Germany (n = 13, all members of the German Neuromyelitis Optica Study Group [NEMOS]), France (n = 5, all members of the NOMADMUS cohort), Austria (1), Italy (1), Switzerland (1), United Kingdom (1), and United States of America (1) were retrospectively analyzed. The evaluated TCZ treatment period ranged from December 2010 until November 2019. Regarding demographic parameters (Table 1) , the mean age at disease manifestation was comparable for patients with MOGAD or AQP4-IgG+ NMOSD (35.5 or 36.1 years, respectively; p = 0.89), as well as the age when TCZ was started (38.4 or 42.8 years, p = 0.35). Five patients were younger than 18 years at disease manifestation, and 3 of them younger than 18 years at initiation of TCZ. Of note, patients with AQP4-IgG+ NMOSD were predominantly female, in contrast to patients with MOGAD (91% vs 35% female, respectively). Patients with AQP4-IgG+ NMOSD tended to have a longer history of disease (median 5.5 years) and were more severely affected at TCZ start (median Expanded Disability Status Scale [EDSS] score 6.25) than patients with MOGAD (median disease duration 2.2 years, p = 0.13; median EDSS score 2.75, p < 0.01). In the MOGAD group, 7 patients (50%) fulfilled the 2015 revised international consensus diagnostic criteria for NMOSD. 35 Before TCZ therapy, patients with MOGAD had had a median of 6 attacks (range 1-12 attacks) with 4.5 ON (median; range 1-10 ON) and 2.0 myelitis events (median; range 1-5 myelitis events). In the NMOSD group, 5/7 double-seronegative (71%) and 27/36 AQP4-IgG+ (75%) patients fulfilled the 2006 NMO diagnostic criteria, 36 whereas all AQP4-IgG+ and double-seronegative patients fulfilled the 2015 NMOSD diagnostic criteria. 35 Of note, 47/57 (83%) patients were tested for both antibodies, and none was double positive. Ten AQP4-IgG+ patients were not tested for MOG-IgG. Before TCZ, all patients had been treated with different immunotherapies following established recommendations, and, remarkably, all had received rituximab (RTX) ( double-seronegative patients) showed markedly reduced or depleted B cells. During the total pre-TCZ treatment phase (median duration of 2.9 years), patients had 6.0 attacks (median; range 1-30 attacks). Considering the last 2 years before TCZ start, 3.0 attacks (median; range 0-10 attacks) were recorded (Table 1) .

All clinical and paraclinical data were analyzed retrospectively by chart review. Patients were continuously treated at the contributing centers, specialized in clinical neuroimmunology, with regular assessment of clinical (attacks, EDSS score, and pain levels) and paraclinical (MRI, AQP4-and MOG-IgG, and other laboratory tests) data. AQP4-IgG and MOG-IgG antibodies were exclusively measured by cell-based assays. The primary outcome was the annualized relapse rate (ARR). An attack was defined as definitely new neurologic symptom or clear acute worsening of previous neurologic deficits with objective clinical signs, lasting for at least 24 hours and attributed to an inflammatory CNS event, confirmed by the treating physician. Safety aspects comprised infusion-related reactions, infections, tumors, cardiovascular events, and standard laboratory tests. AQP4-IgG titers, EDSS score, and chronic pain (occurrence and intensity, classified as mild = 1, moderate = 2, or severe = 3) were assessed at TCZ start and, if available, at last follow-up during TCZ. MRI of the cervicothoracic spinal cord and the brain, evaluated at TCZ onset and last available follow-up, was classified as nonactive or active, indicated by the presence of new T2 or contrast-enhancing lesions.

In general, the ARR was calculated by dividing the number of attacks within the last 2 years before TCZ switch or during TCZ treatment time by 2. However, for 19 patients, who had a TCZ pretreatment phase of <2 years (median 1.1 years), we categorically divided the total number of attacks by 2, and for 13 patients with a follow-up period of <1 year (median 0.5 years) during TCZ treatment, we divided the number of attacks by the concrete treatment duration and thus extrapolated this measure to 1 year. To avoid possible overestimation of the relapse-free proportion in the latter group, we excluded those 13 patients with TCZ treatment durations of <12 months for subgroup analyses.

In the descriptive analysis, values are given as mean or median, with the appropriate measures of dispersion (i.e., range, SD, or IQR). In all cases, the assumption of normal distribution could not be affirmed. Therefore, only nonparametrical tests were used. To test for statistically significant differences between 2 related samples like ARR before TCZ switch and ARR under TCZ therapy, the Wilcoxon signed-rank test was used. In case of paired categorical data with a dichotomous trait, the exact binomial test was used. For count data-like relapses, we also applied an unconditional Poisson regression. Statistical results are presented as p values and 95% confidence intervals. p Values <0.05 were considered to indicate statistically significant results. Because of the exploratory nature of the study, no adjustment for multiple comparisons was made. Version 3.6.3 of the R statistics package was used for statistical analysis.

Standard Protocol Approvals, Registrations, and Patient Consents Ethical approval was obtained from the Institutional Review Board of the Heinrich Heine University Düsseldorf (#3419) and from each participating center by their local institutional review boards according to ICH/GCP. All patients provided written informed consent.

Anonymized data not published within this article will be made available by request from any qualified investigator.

Forty-five of 57 (79%) patients switched to TCZ due to ongoing disease activity, 5/57 (9%) due side effects of prior immunotherapies (including allergic reactions on RTX in 3 patients), and 6/57 (10%) because of concomitant disease activity and adverse events. In 1 patient, the detection of Relapses under last immunotherapy, n: median (IQR)

Relapses during last 2 y before TCZ, n: median (IQR 

Glatiramer acetate 0 (0) 2 (6) 1 (14)

Natalizumab

Long-term plasma exchange

Continued neutralizing antibodies against RTX was the reason for treatment switch. TCZ was administered IV (mean 34 infusions, range 3-109) in 56 patients (98%) at a mean interval of 31.6 days (range 26.1-44.2 days) and with a median dose of 8.0 mg/kg body weight (range 6.0-12.0 mg/kg body weight; ). Additional medications included LDS (n = 10), MTX (n = 4), mycophenolate mofetil (MMF; n = 2), azathioprine (AZA; n = 1), IV immunoglobulins (IVIG; n = 1), RTX (n = 1), and monthly high-dose steroids (HDS; n = 1), administered for <6 months in 3 patients and >6 months in 17 patients during TCZ treatment.

Initiation of TCZ was followed by a decrease of the median ARR in patients with AQP4-IgG+ NMOSD from 1.5 to 0 (p < 0.001, 95% CI 0-0.2) compared with the last 2 

Abbreviations: AQP4 = aquaporin-4; EDSS = Expanded Disability Status Scale; MOG = myelin oligodendrocyte glycoprotein; MOGAD = MOG-IgG-associated disorder; NMOSD = neuromyelitis optica spectrum disorder; TCZ = tocilizumab. a MOG-IgG ab not tested. years before TCZ start. Of note, patients with MOGAD showed a similar median ARR reduction from 1.75 to 0 (p = 0.0011, 95% CI 1.3-2.6). For patients with doubleseronegative NMOSD, median ARR reduction was less prominent but still significant (from 3.0 to 0.2 [p < 0.032, 95% CI 0.3-2.8]). For the total cohort, the median ARR decreased from 1.5 to 0 (p < 0.001, 95% CI 1.1-1.8; Figure 3 ). Of note, ARR reductions were also detectable when analysis was confined to those patients treated with TCZ for at least 12 months, including MOGAD and AQP4-IgG+ NMOSD, but not double-seronegative patients ( Figure 3 ).

Regarding individual patients, 3/14 (21.4%) patients with MOGAD ( Figure 1 ) and 14/36 (39%) patients with AQP4-IgG+ NMOSD ( Figure 2) By comparing the 2 groups of patients who switched to TCZ due to ongoing disease activity or side effects, the median ARR in the first group was 2.0 (IQR 1.0-2.5) during the 2 years prior TCZ and was 0 (IQR 0-0.2) during TCZ treatment, whereas the median ARRs were 1.0 (IQR 0.5-1.0) and 0 (IQR 0-0), respectively, for both intervals in the second subgroup. Figure 4 ).

When including patients with TCZ treatment duration >12 months only, the EDSS score improvement was still significant for AQP4-IgG+ NMOSD and the whole cohort ( Figure 4) . The EDSS score worsened in only 5/57 (9%) patients of the entire cohort, i.e., none of patients with MOGAD, 3/36 (8%) patients with AQP4-IgG+ NMOSD, and 2/7 (29%) double-seronegative patients.

Initial disease-related chronic pain was reported in 28/51 patients (55%), with a median pain intensity of 2.0 (IQR 1-3; data from 27 patients). Presence and intensity of pain were not modulated during TCZ treatment, as 25/52 patients (48%) still had ongoing chronic pain with a median intensity of 2.0 (IQR 1-3; data available from 24 patients) at last follow-up, regardless of the AQP4-IgG/MOG-IgG serostatus.

Regarding AQP4-IgG immunoreactivity, most patients (12/16) showed decreased or stable titers after initiation of TCZ ( Figure 5 for individual courses). Longitudinally assessed MOG-IgG antibody titers were available in only 2 of 14 patients and showed a similar pattern as seen in AQP4-IgG+ NMOSD, i.e., a decrease from 1:320 to 1:32 and from 1:1,280 to 1:10, respectively. during TCZ occurred in 4 patients (2 from each) and led to TCZ discontinuation in 2 of these 19 (11%) patients (both AQP-IgG+ NMOSD). No new cancer occurred. One case of type 1 focal nodular hyperplasia of the liver was diagnosed during TCZ. Cardiovascular events occurred in 3 patients, including a non-ST elevation myocardial infarction after the initial infusion, a deep vein thrombosis, and a slight increase in blood pressure. One death due to recurrent pneumonia occurred 2 months after discontinuation of a 6-month TCZ treatment period, but this was not regarded as treatment related by the treating physician, as the 58-year-old patient had a history of severe AQP4-IgG+ NMOSD with concomitant SLE and uterus carcinoma, including surgery and radiation.

TCZ-treated patients with additional immunotherapies suffered more frequently from pneumonia compared with the monotherapy group (18% vs 6%); other side effects like reactivation of chronic latent infections (5% vs 6%) were equally distributed in both groups.

Neutropenia during TCZ treatment, with a maximum cell count reduction of 61% below the lower reference level, occurred in 10/57 (18%) patients, with 3 patients on a concomitant immunotherapy (MTX, RTX, and LDS; Table 2 ). However, these 10 patients had no higher frequency of common neutropenia-related conditions such as UTI, pneumonia, and other (unspecific) infections. Transient and mild to moderate increases of liver enzymes and lipase (2-to 3-fold above the upper reference level) were reported in 20/57 59-311 mg/dL) to 203.8 mg/dL (n = 44/57; range 85-372 mg/dL; p = 0.5554), with no changes within the subgroups as well. Similarly, low-and high-density lipoprotein (LDL/HDL) cholesterol levels were stable during TCZ (Table 2 ).

Our study designed as a multicenter real-world approach confirms and extends existing evidence, as it shows that in MOG-or AQP4-IgG-mediated inflammatory demyelinating syndromes, IL-6 blockade offers a therapeutic perspective, even if patients were exposed to standard immunotherapies before, including targeted B-cell depletion by RTX. Importantly, our data provide insights into therapeutic long-term management of these diseases, with a follow-up far beyond the observation periods in existing pivotal trials.

MOGAD in adults and NMOSD in general almost exclusively follow a relapsing disease course, 3, 9 emphasizing the relevance of attack prevention for disease prognosis.

Considering the long-term course, MOGAD was assumed to have a less severe prognosis than NMOSD. 37, 38 However, recent studies indicate that retinal neuroaxonal damage and visual impairment after ON are similar in both diseases, suggesting that a higher attack rate in MOGAD, compared with fewer, but more severe ON episodes in AQP4-IgG+ NMOSD, results in comparable tissue damage. 39 Previous case series in NMOSD reported that IL-6R blockade with TCZ confers beneficial effects for attack prevention in retrospective and 1 prospective case series in NMOSD. 20, 24, 40, 41 Moreover, the recent TANGO trial showed that TCZ (n = 56 patients) better prevents NMOSD attacks than azathioprine (n = 52 patients). 42 Finally, 2 recent pivotal trials compared satralizumab with placebo, either as a monotherapy (Sakur-aStar) 14 or as an add-on therapy (SakuraSky) 13 and revealed that satralizumab reduces the relapse rate, particularly in AQP4-IgG+ NMOSD. However, follow-up in these trials was rather short with a range of 60-90 weeks 42 and a median treatment duration in the double-blind period of 107.4 Infusion-related reactions, n (%) 1 (7%) 6 (17%) 0 (0%) 7 (12%)

Recurrent urinary tract infections 1 (7%) 7 (19%) 1 (14%) 9 (16%) Viral upper respiratory tract infections/common cold/bronchitis/ pneumonia 2 (14%) 5 (14%) 2 (29%) 9 (16%)

Oral or lip infections 0 (0%) 4 (11%) 0 (0%) 4 (7%)

Erysipelas and skin lesions compatible with SLE 0 (0%) 3 (8%) 0 (0%) 3 (5%)

Reactivation of chronic latent infection, n (%) 0 (0%) 3 (8%) 0 (0%) 3 (5%)

Tumor, n (%) 0 (0%) 1 a (3%) 0 (0%) 1 a (2%) and 92.3 weeks, respectively. 13, 14 Moreover, real-world NMOSD patient cohorts on TCZ covered a limited number of patients (ranging from 3 to 19) 20,24,40,41 and did not investigate the effects of IL-6R blockade in MOGAD. Of note, 12/36 patients with AQP4-IgG+ NMOSD from this work were previously reported in 4 TCZ-specific studies. 21, 22, 25, 26 In our study on 57 patients including 14 individuals with MOGAD and 36 individuals with AQP4-IgG+ NMOSD, we provide real-world data with a mean and maximum treatment duration of nearly 3 and 9 years, respectively, with 65% of patients receiving TCZ as monotherapy. The mean ARR, as a primary outcome measure, significantly decreased during TCZ treatment by 80% in the total cohort and by 76% in the AQP4-IgG+ subgroup. Of note, our main results-ARR reductions in MOGAD and AQP4-IgG+ NMOSD subgroups and the whole cohort-remained stable when the analysis was restricted to patients receiving TCZ for at least 12 months. Our findings confirm the recent pivotal trials on the beneficial effects of IL-6 blockade by satralizumab in NMOSD, particularly for AQP4-IgG-seropositive patients. We also observed clinical stabilization and reduced spinal cord MRI activity in AQP4-IgG+ patients, along with decreased or stable AQP4-IgG titers in most of them, whereas pain remained constant during TCZ. The decrease of the EDSS score, spinal cord MRI activity, and AQP4-IgG titers could at least in part be explained by fact that baseline values were ascertained during the acute phase and follow-up measures mainly during remission phase while TCZ treatment. Beyond that, the AQP4-IgG titer decrease/stabilization may also be an indirect effect of the IL-6 blockade by TCZ, as IL-6 signaling promotes the autoantibody production from plasmablasts in NMOSD. 18 Our clinical and imaging findings are in line with those in smaller retrospective case series and the TANGO trial. 22, 23, 41, 42 The effect on pain remains ambiguous, as it was reported in smaller case series, 20,22 but was not confirmed in our study or the satralizumab SakuraSky trial. 13 Regarding the patients with double-seronegative NMOSD, we observed a significant ARR reduction, when considering all 7 patients, independently of the treatment duration, which was not reported in the pivotal trials for satralizumab and could be explained by the heterogeneity of this lessdefined patient group, hampering direct comparisons. 13, 14 In line with the satralizumab studies, no effect on EDSS score, pain, and, furthermore, on MRI activity, was detectable in AQP4-IgG+ NMOSD in this study.

For MOGAD, treatment recommendations are scarce, and approaches well established for AQP4-IgG+ NMOSD such as CD20-mediated B-cell depletion have shown limited efficacy in MOGAD. [43] [44] [45] Another MOGAD treatment study showed that under azathioprine therapy, 14 of 17 MOG-IgG+ patients (82%) had at least 1 attack, particularly during the first 6 months and in patients without concomitant steroid therapy. 3 Reports on IVIG or MTX treatment in MOGAD are so far rather anecdotal 3, 46 ; however, recent data revealed the lowest ARR being associated with an IVIG maintenance therapy (n = 10 patients), compared with RTX, MMF, and AZA. 45 Of note, recent findings in a Chinese MOGAD cohort indicate that MMF may prevent relapses, particularly with concomitant oral prednisolone. 47 Compared with untreated adult patients with MOGAD, AZA, MMF, and RTX, but not MTX, mitoxantrone, and cyclophosphamide, significantly reduced the risk of new relapses and the ARR in a cohort of 125 patients. 48 So far, only 14 different MOGAD patients, treated IV and/or subcutaneously with TCZ, were reported in 7 small case reports/series 23, 26, [29] [30] [31] [32] [33] ; 6 of these 14 patients were included in the present cohort.

Here, in our series of 14 patients with MOGAD, the ARR decreased by 93%, the median EDSS score was reduced from 2.75 to 2.0 over a mean TCZ treatment duration of 31 months, and an anti-inflammatory effect was obvious also on brain MRI. Notably, the ARR reduction persisted when considering only those patients who were treated for more than 12 months. Again, the effect on EDSS score and MRI activity was mainly driven by the fact of high disease activity at baseline and remission phase at follow-up assessment. Most patients with MOGAD (79% and 73% for the patients treated for >12 months, respectively) remained relapse free, and in 57% of them, TCZ was used as monotherapy. The remaining 6 patients were cotreated with LDS (n = 4), monthly HDS plus IVIG (n = 1), or MTX (due to psoriasis, n = 1). No effects were found on pain, which is a common symptom in MOGAD, 49 and spinal cord MRI activity. A single attack during TCZ treatment occurred in 21% of patients with MOGAD, 2 or 4 attacks in 14% and 7% of patients, respectively. Our findings are in line with those of a recent study, which showed that TCZ therapy was associated with clinical and radiographic relapse freedom, resolution of eye pain, and ability to discontinue corticosteroids in a cohort of 10 patients with MOGAD over an average treatment duration of 28.6 months. 33 Overall, when considering disease activity, including ARR, as well as suspected side effects during TCZ therapy, we did not observe a clear advantage of add-on treatments, supporting the use of TCZ as monotherapy.

Considering safety, adverse events occurred within the expected range based on the established use of TCZ in clinical practice. Infusion-related reactions appeared in 12% of all patients, and infections of the urinary or respiratory tract were reported with similar frequency. Of note, (re)activation or worsening of chronic latent inflammatory diseases was observed in patients with already established SLE (n = 2) and psoriasis (n = 2), indicating that these patients should be particularly monitored. Laboratory changes included mild to moderate neutropenia in 18% and liver enzyme changes in 35% of patients. Total cholesterol, as well as HDL and LDL cholesterol levels, did not change during TCZ treatment, as expected. 22 An obvious limitation of this study is the retrospective multicenter design resulting in heterogeneity of TCZ treatment regimens and MRI protocols, as well as missing data, e.g., the lack of MOG-IgG testing in 10/36 (28%) AQP4-IgG+ patients. However, the latter issue may not be a serious limitation as co-occurrence of AQP4-and MOG-IgG at significant titers is extremely rare. 50 Another constraint is the relatively small sample size, which is justifiable by the rarity of NMOSD and MOGAD on a concomitant rare and off-label treatment with TCZ. Nevertheless, we attempted to enroll all of these seldom patients from 2 of the largest cohorts in Europe, NEMOS in Germany and NOMADMUS in France, and additional patients from other countries. Moreover, because of the lack of a control cohort and the timing of the switch to TCZ (i.e., during a phase of active disease), we have to consider regression to the mean as an important limitation of our study design, as mean disease activity could decrease spontaneously even without treatment.

Despite these limitations, this largest real-world study supports the long-term safety and therapeutic relevance of the IL-6 pathway in RTX-refractory AQP4-IgG+ NMOSD for up to 9 years. Moreover, our findings suggest a similar role for MOGAD, pointing toward the need for randomized controlled trials to evaluate the efficacy of IL-6 blockade in patients with MOGAD. This study provides Class III evidence that TCZ decreases the probability of relapses in patients with refractory MOGAD and NMOSD. 

Neuromyelitis optica (Devic's syndrome)

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study

MRI differences between MOG antibody disease and AQP4 NMOSD

Time to separate MOG-Ab-associated disease from AQP4-Abpositive neuromyelitis optica spectrum disorder

Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG-and MOG-IgG-associated diseases

The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody

A secondary progressive clinical course is uncommon in neuromyelitis optica

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebocontrolled phase 2/3 trial

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder

Trial of satralizumab in neuromyelitis optica spectrum disorder

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology

Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6

Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder

Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders

Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders

Two cases of pediatric AQP4-antibody positive neuromyelitis optica spectrum disorder successfully treated with tocilizumab

Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a caseseries

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a crosssectional study and potential therapeutic implications

B cell, Th17, and neutrophil related cerebrospinal fluid cytokine/chemokines are elevated in MOG antibody associated demyelination

Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis

Tocilizumab in MOGantibody spectrum disorder: a case report

Reader response: comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment

Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Revised diagnostic criteria for neuromyelitis optica

Clinical presentation and prognosis in MOG-antibody disease: a UK study

Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients

Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy

Blockade of IL-6 signaling in neuromyelitis optica

Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial

Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases

Treatment of MOG-IgGassociated disorder with rituximab: an international study of 121 patients

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

Pain, depression, and quality of life in adults with MOG-antibody-associated disease

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

The authors thank all patients and their families for contributing to our study. Contributing members of the Neuromyelitis Optica Study Group are listed in Appendix 2. MR, IA, GL, IK, and OA had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

The Neuromyelitis Optica Study Group (NEMOS) is partially funded by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS; for NEMOS NationNMO FKZ 01GI1602).Disclosure M. Ringelstein